rs78534766 — ADCY7 ADCY7 D439E

The Immune Brake That Shapes Thyroid Risk

Every cell in your immune system uses cyclic AMP (cAMP) as a molecular brake pedal — a second messenger that dials down inflammatory activation and keeps immune responses proportionate. Adenylyl cyclase 7 (ADCY7) is the enzyme that produces cAMP in lymphocytes¹¹ lymphocytes
white blood cells that orchestrate adaptive immunity, myeloid cells, and thyroid epithelium. The rs78534766 variant swaps one amino acid in ADCY7 (aspartate 439 → glutamate) and cuts the enzyme's cAMP output by roughly 40% — loosening the brake on immune activation.

This is a rare variant. Only about 1 in 100 people of European descent carries even one copy. But when it does occur, the effect is large enough that it stands out in studies involving tens of thousands of people, ranking among the most significant non-HLA coding effects identified in autoimmune disease genetics.

The Mechanism

When ADCY7 carries the D439E substitution, the protein still reaches the cell membrane but produces substantially less cAMP in response to G protein-coupled receptor signals — including the TSH receptor²² TSH receptor
thyroid-stimulating hormone receptor, the primary driver of thyroid cell growth and function on thyroid epithelial cells and immune receptors on T cells and macrophages.

Without adequate cAMP signaling, immune cells shift toward a Th2 phenotype³³ Th2 phenotype
T-helper 2 pattern: characterised by interleukin-4, IL-5, and IL-13 production, which promotes allergic and certain autoimmune responses and simultaneously upregulate surface expression of MHC class II molecules and CD86 (a co-stimulatory signal). The combined effect — more antigen presentation, more co-stimulatory signal, Th2-polarised cytokine environment — creates conditions that favour inappropriate immune activation against self-antigens, including thyroid peroxidase and thyroglobulin.

The Evidence

The initial discovery came from a 2017 whole-genome sequencing study of 16,432 inflammatory bowel disease cases and 18,843 controls by Luo et al.: the ADCY7 missense variant (0.6% MAF) doubled ulcerative colitis risk⁴⁴ the ADCY7 missense variant (0.6% MAF) doubled ulcerative colitis risk and was the most significant non-HLA coding association in the dataset (OR ≈ 2.0–2.16; p = 1×10⁻¹⁴). The same variant has since been replicated in the GWAS Catalog with an OR of 2.16 [1.77–2.62] for ulcerative colitis across independent cohorts.

In parallel, thyroid disease GWAS studies identified the same variant. A 2024 autoimmune hypothyroidism GWAS by Reeve et al. lists ADCY7 among established coding variants with OR 1.46 for autoimmune thyroid disease⁵⁵ OR 1.46 for autoimmune thyroid disease (p = 1×10⁻¹⁴). The 2025 Nature Genetics GWAS by Rand et al. (113,393 hypothyroidism cases, 1,065,268 controls)⁶⁶ (113,393 hypothyroidism cases, 1,065,268 controls) — the largest hypothyroidism genetic study to date — independently confirms the ADCY7 locus at p = 1×10⁻¹⁶.

Mechanistic confirmation came from Cardinale et al. in 2025: cell-based experiments showed the D439E protein retains membrane localisation but produces 40% less cAMP⁷⁷ cell-based experiments showed the D439E protein retains membrane localisation but produces 40% less cAMP. ADCY7 knockdown in immune cells replicated the molecular phenotype — Th2 cytokine skewing and elevated MHC class II + CD86 — explaining the autoimmune predisposition. The authors proposed that enhancing cAMP production (by direct ADCY7 activation or phosphodiesterase inhibition) could be a therapeutic strategy.

Population data shows the A allele is absent in East Asian populations and very rare in African populations, with the highest frequency (~0.6%) in Europeans. Eosinophil counts are also elevated in carriers (GWAS effect 0.097 SD/allele), consistent with a Th2-shifted immune baseline.

Practical Actions

Carrying the A allele means your ADCY7 enzyme is operating at roughly 60% of its normal cAMP-generating capacity. This has two practical implications: (1) earlier and more regular thyroid screening is warranted, since the same immune dysregulation that raises ulcerative colitis risk also raises autoimmune thyroid disease risk; and (2) thyroid peroxidase antibody testing identifies autoimmune thyroid disease years before TSH levels shift.

Selenium has a specific, well-documented role in reducing thyroid peroxidase antibody titres in autoimmune thyroiditis. This is a genuinely genotype-relevant recommendation: the A allele creates an immune environment that promotes antibody-mediated thyroid attack, and selenium supplementation targets exactly that mechanism by supporting selenoprotein-based antioxidant defence in thyroid tissue.

If diagnosed with Hashimoto's thyroiditis or early hypothyroidism, monitoring the free T4/T3 ratio alongside TSH is useful — the GWAS data shows A allele carriers who receive levothyroxine treatment require larger dose adjustments (beta 0.45 dose units; GWAS Catalog GCST90042535), suggesting altered thyroid hormone sensitivity or clearance.

Interactions

The strongest interaction of interest is with other autoimmune loci. Carriers of the ADCY7 A allele who also carry risk variants at immune checkpoint genes (PTPN22 rs2476601, TYK2, IFIH1) face a compounded autoimmune predisposition. These interactions are not yet quantified in published compound heterozygosity studies, but the biological logic is clear — multiple immune regulatory defects are additive.

The ADCY7 variant also shares its cAMP-regulatory pathway with adenylyl cyclase isoforms expressed in the thyroid, suggesting potential interactions with TSH receptor signalling variants (e.g., rs4704397 in PDE8B, which regulates TSH-driven cAMP clearance). Whether carrying both variants additively impairs thyroid cAMP signalling awaits direct study.